{"cluster": 36, "subcluster": 19, "abstract_summ": "Interleukin 1 (IL-1) is a potential target of therapy in COVID-19 during the severe respiratory-inflammatory phase (\"cytokine release syndrome\"), when pulmonary macrophages are hyperactivated, releasing IL-1 and other cytokines.However, researchers and physicians should look for more IL6 receptor antagonists for the therapy of cytokine storm syndrome SARS\u2010CoV\u20102 infected persons to enhance the therapeutic options for cytokine storm.Severe cases of COVID-19 are often attended by a syndrome that has been described as \"cytokine storm,\" with some features shared with macrophage activation syndrome.The purpose of this article is to assess potential pro-inflammatory targets and review the safety and efficacy of immunomodulatory therapies in managing patients with acute respiratory distress syndrome associated with COVID-19.Cytokine storm is a life-threatening complication of Covid-19 infection.This article reviews the occurrence mechanism and treatment strategies of the COVID-19 virus-induced inflammatory storm in attempt to provide valuable medication guidance for clinical treatment.", "title_summ": "Interleukin-3 is a predictive marker for severity and outcome during SARS-CoV-2 infectionsCytokine storm and immunomodulatory therapy in COVID-19: role of chloroquine and anti-IL-6 monoclonal antibodiesInterleukin\u20106 Receptor Antagonist Therapy to Treat SARS\u2010CoV\u20102 Driven Inflammatory Syndrome in a Renal Transplant RecipientPerspective: Cell therapy, SARS\u2010CoV\u20102, COVID\u201019, and James LindInterleukin\u20106 Blockade Treatment for COVID\u201019 associated Cytokine Release Syndrome in a Patient with Poorly Controlled Chronic Myeloid LeukaemiaCOVID\u201019: Consider IL6 receptor antagonist for the therapy of cytokine storm syndrome in SARS\u2010CoV\u20102 infected patientsThe pathogenesis and treatment of the `Cytokine Storm' in COVID-19Lymphopenia in COVID\u201019: Therapeutic opportunitiesGM-CSF-based treatments in COVID-19: reconciling opposing therapeutic approachesCountermeasures to COVID-19: Are immunomodulators rational treatment options \u2014 a critical review of the evidenceAlternative management of Covid-19 infectionIL-6: relevance for immunopathology of SARS-CoV-2Cytokine release syndrome and the prospects for immunotherapy with COVID-19.Part 2: The role of interleukin 1.Role of Interleukin-6 in Lung Complications in Patients With COVID-19: Therapeutic Implications.Practical aspects of targeting IL-6 in COVID-19 disease.", "title_abstract_phrases": "Interleukin\u20106 Blockade Treatment for COVID\u201019 associated Cytokine Release Syndrome in a Patient with Poorly Controlled Chronic Myeloid LeukaemiaIn December 2019, a novel coronavirus pneumonia, coronavirus disease 2019 (COVID\u201019), caused by Severe Acute Respiratory Syndrome Coronavirus 2 (SARS\u2010CoV\u20102) was reported in Wuhan, China.Part 2: The role of interleukin 1.Interleukin 1 (IL-1) is a potential target of therapy in COVID-19 during the severe respiratory-inflammatory phase (\"cytokine release syndrome\"), when pulmonary macrophages are hyperactivated, releasing IL-1 and other cytokines.COVID\u201019: Consider IL6 receptor antagonist for the therapy of cytokine storm syndrome in SARS\u2010CoV\u20102 infected patientsCOVID\u201019 leads to mortality of several patients and the cytokine storm is reportedly critical in the patients.Countermeasures to COVID-19: Are immunomodulators rational treatment options \u2014 a critical review of the evidenceSevere acute respiratory syndrome coronavirus 2 (SARS-CoV-2) is associated with higher concentrations of pro-inflammatory cytokines which leads to lung damage, respiratory failure, and resultant increased mortality.The purpose of this article is to assess potential pro-inflammatory targets and review the safety and efficacy of immunomodulatory therapies in managing patients with acute respiratory distress syndrome associated with COVID-19.Alternative management of Covid-19 infectionCytokine storm is a life-threatening complication of Covid-19 infection."}